Abstract
Summary
Experimental infections with Type XXII pneumococcus, which are refractory to sulfanilamide therapy, can be treated satisfactorily with sulfanilamidopyridine. The amount of drug required for effective treatment is larger than that necessary in Types I, VII, and VIII infections (Whitby). Avirulent decapsulated Type XXII pneumococci have been isolated from the blood of mice treated with sulfanilamidopyridine. This supports the suggestion of Whitby, and Telling and Oliver that the drug exerts a definite action on the pneumococcus capsule.
Get full access to this article
View all access options for this article.